Pharmaceutical Business review is using cookies

ContinueLearn More
November 15, 2018

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.

Image: Merck’s anti-PD-1 therapy Keytruda.  Photo: courtesy of Merck Sharp & Dohme Corp.